Float Short %

22.38

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

0.29

EPS Last/This Y

1.83

EPS This/Next Y

0.81

Price

40.33

Target Price

72.43

Analyst Recom

1.29

Performance Q

-20.34

Relative Volume

1.19

Beta

0.81

Ticker: TARS

19 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	TARS	43.81	0.23	0.00	538
2025-06-03	TARS	43.89	0.23	0.00	538
2025-06-04	TARS	42.6	0.23	0.00	538
2025-06-05	TARS	44.05	0.23	0.00	538
2025-06-06	TARS	43.84	0.22	0.71	543
2025-06-09	TARS	43.11	0.23	12.50	548
2025-06-10	TARS	41.14	0.23	0.53	548
2025-06-11	TARS	40.9	0.22	0.00	563
2025-06-12	TARS	40.98	0.21	0.11	583
2025-06-13	TARS	40.92	0.21	0.19	593
2025-06-16	TARS	41.26	0.21	0.19	593
2025-06-17	TARS	39.38	0.20	0.06	618
2025-06-18	TARS	41.06	0.20	999.99	645
2025-06-20	TARS	40.33	0.20	999.99	646
2025-06-23	TARS	40.5	0.17	4.00	506
2025-06-24	TARS	41.39	0.19	4.00	518
2025-06-25	TARS	40.16	0.19	0.00	517
2025-06-26	TARS	40.29	0.18	999.99	524
2025-06-27	TARS	40.32	0.19	0.00	525
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	TARS	43.83	50.5	-	-1.24
2025-06-03	TARS	43.91	50.5	-	-1.24
2025-06-04	TARS	42.63	50.5	-	-1.24
2025-06-05	TARS	44.08	50.5	-	-1.24
2025-06-06	TARS	43.84	50.5	-	-1.24
2025-06-09	TARS	43.11	50.5	-	-1.24
2025-06-10	TARS	41.17	50.5	-	-1.24
2025-06-11	TARS	40.92	50.5	-	-1.24
2025-06-12	TARS	40.95	50.5	-	-1.24
2025-06-13	TARS	40.90	50.5	-	-1.24
2025-06-16	TARS	41.22	50.5	-	-1.24
2025-06-17	TARS	39.38	50.5	-	-1.24
2025-06-18	TARS	41.07	50.5	-	-1.24
2025-06-20	TARS	40.65	50.5	-	-1.24
2025-06-23	TARS	40.53	50.5	-	-1.24
2025-06-24	TARS	41.38	50.5	-	-1.24
2025-06-25	TARS	40.18	50.5	-	-1.24
2025-06-26	TARS	40.37	50.5	-	-1.24
2025-06-27	TARS	40.33	50.5	-	-1.24
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	TARS	-1.17	9.96	21.46
2025-06-03	TARS	-1.17	9.96	21.46
2025-06-04	TARS	-1.17	9.96	21.46
2025-06-05	TARS	-1.17	9.96	21.46
2025-06-06	TARS	-1.17	9.96	21.46
2025-06-09	TARS	-1.17	10.02	21.46
2025-06-11	TARS	-1.17	10.02	22.27
2025-06-12	TARS	-1.47	10.02	22.27
2025-06-13	TARS	-1.47	10.02	22.27
2025-06-16	TARS	-1.47	10.02	22.26
2025-06-17	TARS	-1.49	10.02	22.26
2025-06-18	TARS	-1.72	10.02	22.26
2025-06-19	TARS	-1.49	10.02	22.26
2025-06-20	TARS	-1.72	10.02	22.26
2025-06-24	TARS	-1.71	9.98	22.28
2025-06-25	TARS	-1.71	9.98	22.28
2025-06-26	TARS	-1.71	9.98	22.38
2025-06-27	TARS	-1.71	9.98	22.38
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.64

Avg. EPS Est. Current Quarter

-0.41

Avg. EPS Est. Next Quarter

-0.35

Insider Transactions

-1.71

Institutional Transactions

9.98

Beta

0.81

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

104

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

36.7

Max Drawdown 5-Year %

Target Price

72.43

P/E

Forward P/E

33.07

PEG

P/S

7.25

P/B

4.95

P/Free Cash Flow

EPS

-2.73

Average EPS Est. Cur. Y

-1.24

EPS Next Y. (Est.)

-0.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-44.91

Relative Volume

1.19

Return on Equity vs Sector %

-54.5

Return on Equity vs Industry %

-36.7

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.25

EBIT Estimation

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: TARS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y